

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68		(11) International Publication Number: WO 95/20053
A1		(43) International Publication Date: 27 July 1995 (27.07.95)
(21) International Application Number: PCT/GB95/00109		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).
(22) International Filing Date: 20 January 1995 (20.01.95)		
(30) Priority Data: 9401200.2 21 January 1994 (21.01.94) GB		
(71) Applicant (for all designated States except US): MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, Regents Park, Great Portland, London W1N 4AL (GB).		
(72) Inventor; and (75) Inventor/Applicant (for US only): SIBSON, David, Ross [GB/GB]; 37 Grimsdells Lane, Amersham, Bucks HP6 HF (GB).		
(74) Agents: BIZLEY, Richard, Edward et al.; Hepworth Lawrence Bryer & Bizley, 2nd floor, Gate House South, West Gate, Harlow, Essex CM20 1JN (GB).		

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SEQUENCING OF NUCLEIC ACIDS

(57) Abstract

The present invention provides a method of sequencing a nucleic acid, comprising either sequentially removing bases from the sequence of the nucleic acid a predetermined number at a time, with the product remaining from each step of predetermined base removal being ligated to a labelled adapter specific for said bases and including oligonucleotide sequence, or hybridising a primer to the nucleic acid to be sequenced and sequentially extending said primer a predetermined number of bases at a time, said added base(s) being complementary to base(s) in the nucleic acid being sequenced, and each of said base addition steps being achieved by the use of a labelled adaptor specific for said bases and including oligonucleotide sequence containing said predetermined base(s); in either case, the label of said labelled adaptor being specific for its respective predetermined base(s).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Sequencing of Nucleic Acids

5 This invention relates to new techniques for the sequencing
of nucleic acids based upon a general approach in which
labelled adaptor molecules are employed. The invention
facilitates the large scale analysis of populations of
nucleic acids, for example populations of sequences as
10 produced in the Human Genome Project (HGP). Its
applicability is, of course, not limited to HGP or its
like.

Conventional analysis of nucleic acid sequences has
hitherto depended largely on the base specific
15 fragmentation of the original nucleic acid sample into two
or more parts differing in size by one or more bases.
Sequencing is effected by separation of the resultant
fragments followed by their analysis.

20 In relatively low throughput sequence analysis of RNA, base
specific fragmentation has been effected by ribonucleases
with base specific activities, followed by thin layer
chromatographic separation of the products. Higher
throughput sequence analysis, especially of DNA, generates
25 the fragments to be analyzed by base specific chemical
cleavage (Maxam, A.M. and Gilbert, W Proc. Natl. Acad Sci.
74 p560 (1977) or by terminating, in a base specific
manner, synthesis catalysed by a suitable nucleic acid
polymerase (Sanger, F., Nicklen, S and Coulson, A.R., Proc.
30 Natl. Acad Sci. 74 p5463 (1977)). Separation of the
resultant fragments is achieved by denaturing gel
electrophoresis through ultra thin slabs or capillaries
containing a suitable polymer like polyacrylamide. This
can resolve of the order of about a thousand bases per
35 suitably prepared sample at a resolution of one base, and
can handle tens of samples simultaneously. Detection

(Smith, L., M. and Youvan, D., C. Biotechnology 7 p576-580 (1989)) (Yang, M., M., and Youvan, D., C., Biotechnology 7 p576-580 (1989)) has been direct or indirect through radioactive, chemiluminescent or fluorescent labelling or
5 by stable isotopes (Human Genome 1991-1992 Program Report p18 and p22 U.S. department of Energy 1992)).

There is a great deal of interest in achieving greater rates of sequencing at reduced cost. It will then be
10 feasible to analyze completely the genomes of organisms, in particular those of higher eucaryotes which are commonly over 3,000,000,000 bases in size per haploid genome. Furthermore, methods which are suitable for such analysis will also make it possible to perform high resolution
15 linkage analysis on many individuals in a population. This will be important for identifying the phenotypes, especially common diseases, associated with genes, and to trace gene flow in humans. Analyzing the expressed sequences in a population of cDNAs or mRNAs would also
20 become possible. It would also be possible repeatedly to sequence the same region or multiple regions from many different individuals for the purposes of comparisons related to for example diagnosis.

25 Very high throughput methods of sequence analysis are therefore being investigated (desirably one or more orders of magnitude greater than achievable with current, conventional, commercially available sequencing apparatus, such as the ABI 373 DNA sequencing System which can read
30 not more than 1000 bases a day from 72 samples). Scanning tunnelling electron microscopy can directly visualise the bases in individual molecules. Lasers might also be usable to sort individual molecules, which can then be analyzed by degrading them from one end, a base at a time (Harding,
35 J.D. and Keller, R.A. Trends in Biotech 10 p55-58 (1992)).

However, there is a further problem when it is desired to conduct sequence analysis at a rate adequate for analyzing whole genomes or adequate for comparing many selected sequences from many individuals (for example, when using family studies to identify the locus of an inherited trait), namely many samples need to be simultaneously analyzed. This is currently being approached through sequencing by hybridisation.

There are two formats for sequencing analysis by hybridisation. One format (Drmanac, R., et al Genomics 4 p114-128 (1989) and Stretzoska, Z., et al Proc. Natl. Acad. Sci USA 88 p10,089-10,093 (1991)) immobilises many samples (perhaps numbering hundreds of thousands) separately on a large array. The array is probed in turn by each of many different labelled oligonucleotides of known sequence. Identification of samples which have hybridised to each of the probes, indicates those which have complementary sequences to the probe. Use of multiple probes covering all possible sequences allows the complete sequences of the samples to be assembled. This method is, however, limited by the requirement for oligonucleotides of at least 5 bases to achieve specific hybridisation, which in turn dictates that large numbers of probes (4^n where n is the length of the oligonucleotide) are required to cover all possible sequence combinations.

The alternative format (Fodor, S. et al Nature 364 P555-556 (1993), Kharpmko, K., R., et al DNA Sequence 1 p375-388 (1991), Southern, E., M., Maskos, U., and Elder, J., K. Genomics 13 p1008-1017 (1992)) requires many thousands of different oligonucleotides, each with different known sequence covering together all possibilities, to be immobilised on a suitable array. Probing the array with a

labelled nucleic acid sample whose sequence is to be analyzed identifies the oligonucleotides which share homology with the sample. This is usually achieved through synthesis of the oligonucleotides *in situ* with masking, for example by a lithograph, of those not requiring the specific base being added at any given time. The sample is labelled and hybridised to the array. The positions of hybridisation indicate where sequence homologies are shared between the sample and the detected oligonucleotides. Therefore the sequences of the sample can be deduced from those of the detected oligonucleotides.

In either format for sequencing by hybridisation, it is difficult in practice to synthesise oligonucleotides of adequate length. When oligonucleotides are immobilised and probed with sample, in practice only short oligonucleotides can be synthesised on arrays of necessarily limited size.

Alternatively, and as mentioned above, when oligonucleotides are synthesised independently to probe an array of samples, the number required to cover all sequence possibilities is 4^n , where n is the length of each oligonucleotide. It is logistically challenging both to produce and to use the number required to accurately detect all possible sequences. For example, the number required to make all possible 5 mers is 1024.

The length of the oligonucleotides determines their fidelity of hybridisation, and also the ease with which full sequence can be assembled from the component oligonucleotide sequences. In each case longer oligonucleotides are better. Greater fidelity of hybridisation is achieved the longer the oligonucleotides used since more stringent washing can be performed when the oligonucleotides are as long as possible. When full length

sequence is being assembled from overlapping component sequences, the longer the component sequences the fewer possible "solutions" that there are likely to be.

5 A further problem associated with the sequencing by hybridisation format where probe oligonucleotides are immobilised is that as the size of the target increases the proportion of any given region within that target decreases. This reduces signal to noise, and therefore has
10 the effect of limiting the size of target, which can be analyzed.

Hybridisation used alone, is in general not a good means of analyzing sequences because not all oligonucleotides
15 hybridise with equal efficiency or specificity under a given range of conditions. There are therefore associated interpretational and/or practical difficulties.

The possibility for enzymatic sequencing *in situ* on arrays
20 of immobilised samples has also been reported (Rosenthal, A. and Brenner, S. 1993 Meeting on Genome mapping and sequencing page 222 Cold Spring Harbor Laboratory Press (1993). Each base is labelled differently and added to the samples such that extension is terminated at a given base.
25 The number and type of added bases is recorded for each sample. The block to extension is removed so that the exercise can be repeated for the next base to be so tested. Cycles of testing each base in turn produces complete sequence for each sample. This method suffers the
30 difficulties of distinguishing the number of members in a homopolymeric sequence and that different molecules within a given sample become out of phase with each other with respect to the position of the bases being analyzed.

35 A method of sequentially determining the order of bases one

or more bases at a time on many samples simultaneously would be attractive if available because it could be automated, would require few reagents and might allow of the order of tens of bases to be determined which would facilitate assembly of full length sequence. Each sequence of 17 bases, for example, excepting the repetitive elements which comprises a low complexity special case, is likely to be unique in the human genome. Producing overlapping sequences of 17 or more bases from the human would therefore facilitate assembly of the unique human sequences. In order for such a process to be successful it is necessary to determine the order of bases on all samples one or more at a time without allowing molecules within any of the samples to become out of phase during the process. This is achieved for the first time by the present invention.

The present invention is based upon the use of specific adaptors including oligonucleotide sequence comprising one or more predetermined bases. In some embodiments of the invention, use is also made of restriction endonucleases having a recognition site displaced from the cleavage site. All embodiments depend, however, upon the use of the aforementioned adaptors.

Thus, the present invention provides a method of sequencing a nucleic acid, comprising either sequentially removing bases from the sequence of the nucleic acid a predetermined number at a time, with the product remaining from each step of predetermined base removal being ligated to a labelled adapter specific for said bases and including oligonucleotide sequence, or hybridising a primer to the nucleic acid to be sequenced and sequentially extending said primer a predetermined number of bases at a time, said added base(s) being complementary to base(s) in the nucleic

acid being sequenced, and each of said base addition steps being achieved by the use of a labelled adaptor specific for said bases and including oligonucleotide sequence containing said predetermined base(s); in either case, the
5 label of said labelled adaptor being specific for its respective predetermined base(s).

The predetermined base removal embodiments are best suited to double stranded nucleic acids, and the technique can use
10 nucleases as described herein. Of course, any other appropriate method of base specific cleavage can be used if desired.

Thus, a further aspect of the invention is a method of
15 sequencing a population of double stranded nucleic acids, comprising:-

(a) ligating to said nucleic acids adaptors which include double stranded oligonucleotide sequence
20 which incorporates a predetermined nuclease recognition sequence for a nuclease whose recognition site is displaced from its cleavage site, said displacement being such as to create, as a result of said ligation, cleavage sites in
25 the resulting ligation products which, upon cleavage thereat, result in removal of a base or bases from one strand of said nucleic acids;

(b) cleaving ligation products from (a) with said
30 nuclease to produce double stranded products of unequal strand length;

(c) subjecting said products from (b) to ligation with a population of adaptors which include
35 double stranded oligonucleotide sequence having

5 extending single strands wherein said population
of adaptors includes molecules having in their
extending single strands at least a predetermined
subset of all possible permutations of a base or
bases constituting a predetermined number of
bases, and wherein each permutation is provided
with a respective unique and detectable label,
each adaptor in said population having a nuclease
recognition sequence for a nuclease whose
10 recognition site is displaced from its cleavage
site, said displacement being such as to create,
as a result of the ligation of this step (c),
upon cleavage thereat, result in removal of a
base or bases from one strand of said products
15 from (b);

- (d) separating the ligation products from (c);
- (e) cleaving the separated ligation products from (c)
20 with the nuclease of (c) to produce a population
of fragments carrying the recognition site of the
nuclease of (c);
- (f) either analyzing the labels carried by ligation
25 products separated in (d), or analyzing the
labels carried by fragments from (e); and
- (g) repeating steps (c) to (f) as often as necessary
to determine the desired sequence, but with the
30 final repeat optionally omitting step (e).

Preferably, in (c) above, all possible base permutations
would have a unique label, but it is sufficient to label a
subset of the permutations as long as analysis is not
35 wished to proceed at a rate greater than determined by the

proportion of the permutations which are labelled. For example, a 4 base extension has 256 permutations. If 16 "colours" were available as labels, all of the permutations of possible bases at 2 of the 4 bases in the extension could be labelled and deleted independently. Of course, only "bases worth" of information would be determined.

As will be clear from the description hereinafter, it will be appreciated that the "predetermined number of bases" referred to in (c) above is the base or bases which are being monitored for sequencing purposes. The number of such bases can be one or more.

Although the above process is defined by reference to nucleases and nuclease cleavage and recognition sites, other means of achieving the same effect of stepwise base removal are expressly envisaged by the invention and not excluded. Obviously, the use of particular restriction endonucleases (see below) is very convenient and preferred but is not absolutely essential.

Preferably, the above process is preceded by treatment of the population of nucleic acids with the nuclease(s) to be used later in the process.

Other aspects of the invention are the use of the nuclease having a recognition site displaced from its cleavage site in the sequencing of nucleic acid, and a kit for sequencing nucleic acid which comprises at least one nuclease having its recognition site displaced from its cleavage site and/or a population of double stranded oligonucleotides in which the strands are of unequal length with one or more predetermined bases in the extending strand and with the double stranded portion including a recognition site for a nuclease having its recognition site displaced from its

cleavage site.

Preferably, there is a recognition site for more than one
nuclease because the choice can be exercised as to which
5 nuclease is to be used for base specific removal. This
would be an advantage, for example, when there is already
a site for one nuclease in the sample being sequenced, but
not the other. It is practical to fit more than one
recognition site in the oligonucleotides or adaptors
10 provided the sites do not overlap. Alternatively, a
plurality of sites works if the sequences of the
recognition sites either are partially the same in a way
which will accommodate partial overlap without either
recognition site being altered. The same "types" of cut
15 ends must also be generated by the enzymes. For example,
the recognition site for a nuclease which produces a 3'
overhang would preclude the simultaneous use of a
recognition site for a nuclease which produces a 5'
overhang.

20

The predetermined base addition embodiments of the
invention are best suited to sequencing a single stranded
nucleic acid provided with at least some known sequence.
Accordingly, another aspect of the present invention is a
25 process for sequencing single stranded nucleic acid having
or being provided with at least some known sequence,
comprising:-

- 30 (a) annealing an oligonucleotide primer to said known
sequence immediately adjacent to the unknown
sequence to be determined in said nucleic acid;
- (b) subjecting the end of said oligonucleotide
immediately adjacent to the unknown sequence to
35 ligation with a population of labelled adaptors

having oligonucleotide sequence including all possible permutations of a predetermined number of bases positioned at the end thereof which is so-ligated, the adaptors of said population being employed simultaneously, in preselected groups, or one by one, as desired;

(c) detecting the specific adaptor from said population which was ligated in (b);

(d) removing all of said specific ligated adaptor except for said one or more predetermined bases thereby to extend the double stranded region of the resulting product; and

(e) repeating steps (b) to (d) to the necessary extent to determine the unknown sequence, but with the final repeat optionally omitting step (d).

Since all processes in accordance with the present invention require the use of labelled adaptor molecules which are preferably, but not essentially, entirely constituted by an oligonucleotide, it is important to note the nature of the label in question is not significant to the invention. Any workable means of detecting with specificity particular adaptors, whether in ligated condition or not, and hence the particular predetermined bases they carry, is adequate for the purposes of the present invention. Useable labels include those known to the skilled person, for example, radioactive isotopes, stable isotopes, homologous or similar sequences, dyes, fluorescent compounds, enzymes, biotin, carbohydrates. The term "label" is to be broadly construed to cover an entity which can be detected by any means without undue

interference with the sequencing process.

5 This invention will now be further described in detail with reference to the various categories of embodiment discussed above.

10 Turning first to the aspect of the invention which is constituted by the predetermined base removal process, it will be noted that this process takes advantage of the certain category of restriction endonucleases selectively to degrade all samples simultaneously by a predetermined number of bases from one end, and to record the bases at each modified end either just before or just after degradation. Cyclical repetition of the process generates
15 lengthy sequence information of the order of tens of bases from the sample ends.

Nucleases which can be employed in this process include restriction endonucleases the cleavage sites of which are
20 asymmetrically spaced across the two strands of a double stranded substrate, and the specificity of which is not affected by the nature of the bases adjacent to a cleavage site. Type II restriction endonucleases of these types together cover a wide range of specificities, are readily
25 available, and are highly specific and efficient in their action (Review: Roberts, R. J. Nucl. Acids res. 18, 1990, p2331-2365).

30

Table 1

Enzymes whose cleavage site is outside of their recognition site and are therefore suitable for use in sequencing by base removal.

AlwI	GGATC(4/5)
BbsI	GAAGAC(2/6)
BbvI	GCAGC(8/12)
Bce83I	CTTGAG(16/14)
BceII	ACGGC(12/13)
BcgI	(10/12)GCAN6TCG(12/10)
BpmI	CTGGAG(16/14)
BsaI	GGTCTC(1/5)
BsgI	GTGCAG(16/14)
BsmAI	GTCTC(1/5)
BspMI	ACCTGC(4/8)
EarI	CTCTTC(1/4)
Eco57I	CTGAAG(16/14)
Esp3I	CGTCTC(1/5)
FauI	CCCGC(4/6)
FokI	GGATG(9/13)
HgaI	GACGC(5/10)
HphI	GGTGA(8/7)
MboII	GAAGA(8/7)
MmeI	TCCRAC(20/18)
MnII	CCTC(7/6)
PleI	GAGTC(4/5)
RleAI	CCCACA(12/9)
SapI	GCTCTTC(1/4)
SfaNI	GCATC(5/9)
TaqII-1	GACCGA(11/9)
TaqII-2	CACCCA(11/9)
Tth111II	CAARCA(11/9)

Thus, the predetermined base removal process makes use of base specific cleavage towards the end of samples to be analysed. Of course, it is possible (and this is generally likely to be the case) that the samples being analysed will include sequences having a nuclease cleavage site internally. Such samples must be pre-prepared such that the base specific cleavage employed does not occur internally as well as at the desired end. One means of achieving this is to pretreat sample with the appropriate nuclease or nucleases such that the resulting fragments cannot thereafter be cleaved by such nuclease(s). In effect, sequence analysis is then confined to the ends of the resulting fragments. If desired, a known pattern of pre-cleavage involving selected nucleases can be employed before the performance of the present process, using not only nuclease enzymes subsequently to be employed in the process but other nucleases in addition.

Additionally, nucleic acid samples to be sequenced can be prepared so that they can be simultaneously treated by the process and analysed without interference between individual nucleic acids. One means of achieving this is to have each nucleic acid in a separate reaction vessel. The invention, however, readily lends itself to preferred simultaneous processing and analysis of many samples in the same reaction vessel, with nucleic acids distinguishable in that vessel by the use of independent immobilisation.

Preferably ligation reactions used in the processes of the present invention are catalyzed by DNA ligase, which enzyme is, of course, readily available and easy to use.

The general scheme of the predetermined base addition method is illustrated in the attached Figure 1. In the scheme shown in Figure 1, for purposes of illustration a

single restriction endonuclease is employed, namely Bsa I. However, the predetermined base removal aspects of the present invention are not limited to the use of a single predetermined nuclease. If desired, a predetermined
5 pattern of use of different nucleases can be employed at different stages during the sequencing operation.

In the scheme shown in the attached Figure 1, fragments to be analysed are first created by Bsa I, which is also
10 utilized for the stepwise base specific analysis of the ends. This avoids the possibility of the enzyme cutting internally during analysis until such time as the sequence is "used up" as a result of stepwise degradation.

15 In a large nucleic acid, on average the fragments can be classified into three types dependent on whether (and how) or not they retain the BsaI recognition site. One type will have BsaI at neither of its ends. One type will have BsaI recognition sequence at one of its ends, one type will
20 have BsaI recognition sequence at both of its ends. On average they will be in the proportion 1:2:1, respectively. In this case analysis is confined to those fragments which completely lack BsaI recognition sequence. There are many ways that one skilled in the art can select for the
25 required fragments and instances of these can be found in the Examples hereinafter. Additionally, there are ways that one skilled in the art can select for the removal of BsaI recognition sequence from ends where such sequence does occur. One such method would be to ligate to BsaI cut
30 DNA, in the presence of active BsaI, adaptors with a BsaI recognition sequence whose use will result in removal of bases from the nucleic acid sample being sequenced. Once an adaptor has ligated there are two possible outcomes at each cleavage which follows. Either the BsaI site in the
35 fragment is used, in which case part of the adaptor is

cleaved off. Alternatively, the BsaI site of the adaptor is utilised in which case bases are removed from the sample. Cycles of addition and cleavage will ensue. Eventually by chance the BsaI site of the sample will be removed and further cleavages will be from the sample. Suitable titration will determine the level of treatment required to give a population sufficiently depleted in BsaI, but not overly reduced in average size by digestion from the adaptor. This is in fact, a general way of exposing internal sequences to the sequencing process. Other such methods are known (for example treatment with DNase I in the presence of manganese²⁺, treatment with BaI31 or by random shearing (Sambrook, J., Fritsch, E.G. and Maniatis, T. ed (1989). "Molecule Cloning". Cold Spring Harbor Laboratory Press, New York)).

Importantly, in the scheme shown in Figure 1, two general types of adaptor molecule are utilized.

The first type of adaptor molecule, shown in Figure 1 as an oligonucleotide as such, contains base sequence which includes the recognition site for Bsa I. The location of the Bsa I recognition site within the adaptor is such that upon ligation with blunt ended nucleic acid sequences of interest and subsequent cleavage by Bsa I, a selected number of bases will be removed from the end of the nucleic acid being analyzed, thus exposing complementary bases for analysis. This requires that the number of bases in the adaptor between the recognition site and the point of cleavage is fewer, by the number of bases to be removed from the nucleic acid being sequenced (the predetermined number of bases), than the maximum cutting distance of the enzyme Bsa I from its recognition site.

Of critical importance for the continuing cyclical nature

of the process is that whichever endonuclease is employed, it should not cut to leave a blunt end. The overhang or extending strand which remains can be either 3' or 5' depending upon the nature of the cleavage which is produced.

In Figure 1 it can be seen from the first stage that the adaptor molecules used have a recognition site for Bsa I which is situated four bases from the oligonucleotide sequence end which is to be ligated to the nucleic acid to be sequenced. Since Bsa I cuts five bases away from its recognition site to leave a four base 5' overhang, upon cleavage one predetermined base is therefore effectively removed from nucleic acid being sequenced. Of course, if required, more than one base may be removed, with the number of the bases at the end of the adaptor molecules being reduced by the number of additional bases (the number of additional predetermined bases) that it is required to remove. Thus, in the case of Bsa I a maximum of five bases can be removed. As will be seen below, later detection steps can, however, only analyze the bases in the overhanging strand and it is therefore appropriate not to leave less than one base beyond the recognition site. The number of new bases exposable for analysis in subsequent cycles is equal to the shortest distance between the recognition site and the cleavage site. In the case of BsaI this is one, but it is more than one in the cases of other enzymes, e.g. FokI where it is nine.

In Figure 1, the nucleic acids to be sequenced in the population which is being examined (two for the purposes of illustration) have been independently immobilised to solid phase, exposing the non-immobilised ends to sequence analysis. The first stage in the overall process is that the thus-exposed ends are ligated to the adaptor molecules

and residual adaptor molecules washed away. Bsa I is then added, and this effectively removes both the ligated adaptor and the preselected number of bases (as shown in the Figure, one base is removed). Enzyme and cleaved
5 adaptor are then washed away.

In the next stage, a different population of adaptor molecules is employed. These adaptors are of the second of the two types mentioned above. These adaptor molecules
10 have an extending strand in that portion of the molecule which is an oligonucleotide sequence, with the extending strand of each adaptor having a known and different base specificity. A population of adaptor molecules is employed that, in effect, is capable of reporting all possible
15 combinations of permutations of predetermined base specificities. Moreover, each adaptor has both a detectable label which is specific for the particular base or bases which are predetermined in each adaptor and a nuclease recognition site as described above.

20 Preferably, the entire population of the second type of adaptors are then ligated to the cleavage product resulting from the previous stage of the process under conditions such that only adaptors where the extending strand exhibits
25 actual complementarity for the extending overhang in the cleavage products will ligate. Such conditions, for example (but not essentially), could utilise 1 pmole of cleavage product, 200 pmoles of adaptors, and 0.25 units of T4 DNA ligase, at a temperature of 16°C for 4 to 16 hours
30 in a 50 ul reaction volume also containing 20mM Tris-HCl pH7.5 @ 24°C, 50mM sodium chloride. 10mM magnesium chloride, 1mM adenosine triphosphate and 1mM dithiothreitol. The conditions of time, temperature and ionic strength may be varied by one skilled in the art to
35 achieve the required rates of ligation and specificity.

Of course, in the alternative each adaptor molecule at this stage could be ligated in turn with each nucleic acid sample being examined to determine whether it ligates or not. However, it is preferred that the population of adaptor molecules employed comprise molecules each having a different base specificity with a corresponding specific label. In this way, the adaptor molecules can be ligated simultaneously and, after washing away unused (unligated) adaptors, those adaptor molecules which have actually ligated can be determined and distinguished.

For the purposes of illustration in Figure 1, the uppermost nucleic shown becomes green by ligating to the base C-specific adaptor molecule, while the lowermost nucleic acid shown becomes red by ligating to the base A-specific adaptor molecule.

Essentially, there are two ready options for analysis. In the first option, detection of the specific adaptor molecules which have successfully ligated with nucleic acid sequences can be performed whilst these molecules remain ligated. This is shown as Analysis Option 1 in Figure 1. Such an option is preferred when many samples are being analyzed in the same reaction vessel, and the process can be both sensitive and inexpensive. Thus, nucleic acid samples could be immobilised each to separate one to five micron diameter beads which are generally commercially available. Over one million beads could then comfortably be analyzed using standard fluorescence microscopy coupled with image analysis. Reaction volumes would be very small, with consequent reduction in reagent costs. An alternative analysis option, Analysis Option 2 as shown in Figure 1, exists once the products of ligation including the labelled adaptors are subjected to further action of the restriction

enzyme, Bsa I. Because the adaptor molecules which are labelled also carry the recognition site for Bsa I, cleavage is again possible. As before, the recognition site is deliberately positioned in the oligonucleotide portion of such adaptor molecules such that one or more predetermined bases are removed from the end of each nucleic acid sequence being analyzed to leave an extending strand. In Figure 1, Bsa I removes the adaptor molecules together with the end base from each nucleic acid. The number of bases removed at this stage of the process can obviously depend upon the positioning of the enzyme recognition sequence in much the same way as described above in relation to the first stages in the process.

In any event, as a result of the immobilisation of the original sequences to be determined, after the second Bsa I cleavage in the overall process a population of specific adaptors is released which can be analyzed for their particular labels in Analysis Option 2. Analysis of the labels produced by this process obviously gives base specific information derived from the nucleic acid sequences being analyzed.

In Analysis Option 2, adaptor molecules may, if desired, be detected by the use of robotically controlled sampling and off-line detection. Robotic liquid handling is becoming commonplace in molecular biology applications (Uhlen, M., et al Trends in Biotech 10 p52-55 (1992)).

As can be seen from Figure 1, the first cycle of ligation and analysis is now complete. Thus, after the first stage, each cycle of the process thus comprises ligation of labelled adaptors, followed by either: (a) detection of the particular label followed by removal of the adaptors plus a predetermined number of end bases from the nucleic acid

sequence; or (b) removal of the adaptors plus one or more predetermined end bases from the nucleic acid followed by label detection.

5 To continue the process, a new cycle must be started. A new cycle of ligation of adaptor molecules is therefore performed as described before to determine which bases are now present at the degraded nucleic acid sequence ends. In Figure 1, in the second cycle, the uppermost nucleic acid
10 turns cyan through ligation of a base G-specific adaptor, and the lowermost nucleic acid turns blue through ligation of a base T-specific adaptor.

The process is repeated with cycles of ligation of labelled
15 adaptors, washing and detection of labels and removal of adaptors to expose the next base or bases until the desired number of bases have been analyzed at the ends of the nucleic acids being examined or the entirety of the sequences have been determined.

20 At the very last stage, when the last base or bases is/are being determined it is, of course, optional and dependent upon other features of the process whether or not a final cleavage step is employed. Using Analysis Option 1, no
25 final cleavage step is necessary.

It will be appreciated that the structure of the adaptor molecules which comprise oligonucleotide sequence is important to the sequencing process just described. In
30 practice, the only limitation on the number of different adaptor molecules that can be employed is the number of distinguishably different labels that are available for determination of adaptor specificity at subsequent stages in the process. Availability of a large number of adaptor
35 molecules which are individually specifically labelled has

the advantage that more than one base at a time can be analyzed per cycle. Thus, by way of example, removing two bases at a time would require the use of 16 different adaptor molecules each having a different and distinguishable label. When 16 different labels are available, it is possible simultaneously to analyze all the possible products. In general terms, the number of adaptor molecules required is 4^n , where n is the number of bases to be analyzed per nucleic acid per cycle.

10

It is also possible to analyze each base in the sequences more than once. This can be achieved by using more adaptor molecules than there are bases removed per cycle. For example, if during each cycle 16 different distinguishably labelled adaptors are used, each adaptor recognizing a unique combination of two different bases, then on the cycle that a given base is first exposed at the end of the nucleic acid being degraded and sequenced it is detected as a result of the specificity of the base at the extreme 5' end of the complementary bases in the labelled adaptor (see Figure 1). However, one cycle later the same base will be detected by the penultimate base in the adaptor molecule.

20

The precise structure of the (second type - see above) adaptor molecules used in the above process is not critical, except that an oligonucleotide portion must obviously be included which has appropriate sequence to provide nuclease recognition site and one or more predetermined bases, and the adaptors must carry predetermined base-specific labels.

25

30

It is not essential that bases in adaptor molecules that are used to detect exposed bases in the nucleic acid sequence being degraded be at the extreme ends of the extending strands in the adaptors, merely that they are

35

contained within the extending strand. The precise position of such base or bases merely determines when, in the overall process, they will be read.

5 Most preferably, adaptors in the invention are short double-stranded oligonucleotides which can be joined to the ends of cleavage products. They will have been chemically synthesised so that their sequence can be predetermined and so that large concentrations can be easily produced. They
10 may also be chemically modified in a way which allows them to be easily purified during the process. Ideally their 5' ends will be unphosphorylated so that once joined to degraded nucleic acid fragments, the adapted end of the latter will no longer be able to participate in further
15 ligation reactions. The risk of inappropriate ligation involving adaptors is thus avoided.

Occasionally in the processes of the present invention which operate by sequential predetermined base removal,
20 instances could arise where a new cleavage site for the restriction endonuclease(s) will be created by ligation of labelled adaptor to degraded nucleic acid sequence. This will be detected when more than one type of adaptor from the range of adaptors used will be able to ligate to the
25 nucleic acid, unless the same bases are exposed by the respective cleavages which are occurring. In the latter case, this eventuality will be detected by the process during the cycle when the sequences diverge.

30 To eliminate the above mentioned possibility of new cleavage site formation, the use of enzyme recognition sites is avoided which can donate one or more bases in the direction of cleavage to one or more bases and create in the process an additional recognition site like the
35 original but displaced (in the direction of cleavage) from

the original. Furthermore, it is desirable to avoid placing, in the part of the adaptor which is between the recognition site and the cleavage site, one or more bases from the side of the recognition site which is away from the cleavage site in the order in which they occur in the recognition site, thus preventing the possibility of the nucleic acid being sequenced donating the necessary bases to create a new recognition site like the original recognition site but displaced from the original in the direction of cleavage. Other similar measures would be effective.

Moving on now to predetermined base addition processes of the invention, as has been indicated above the invention includes embodiments in which bases are added one or more at a time to an oligonucleotide primer which is annealed to a known sequence immediately adjacent to unknown nucleic acid sequence to be determined. This is generally illustrated in Figure 2, and is, of course, suited to single-stranded nucleic acids. After such annealing, the next stage in this particular set of embodiments is exposure of the duplex thus-created to ligation with a population of adaptors carrying one or more predetermined bases at the end of an oligonucleotide sequence. As with other embodiments of the invention, there is an interrelationship between the number of predetermined bases and the number of available labels used to detect the particular predetermined base or bases.

Apart from the oligonucleotide end of the adaptor molecules (which is critical to the extension process at the heart of such base addition embodiments for sequencing nucleic acids), the remainder of the structure of these particular adaptor molecules should ideally be non-specific to facilitate ligation, or need not even be nucleotide

sequence provided that the actual nature of the molecule is such as not to interfere with the process of the invention.

5 As will be recalled, the next stage in the process is detection of the specific label or labels following adaptor ligation. This, of course, identifies the particular base or bases which have been added to the primer and, in turn, identifies the complementary bases in the nucleic acid strand which is being sequenced.

10 The final step in a cycle of this process is removal of all of the adaptor molecule except for the one or more predetermined bases which have extended the double stranded region of the primer/nucleic acid duplex. As will be
15 appreciated, repeating cycles generates sequence information for the single stranded sequence being determined.

20 At the stage in each cycle when removal of the non-specific part of the adaptor molecules is effected, the means for doing this can be enzymatic or chemical with adaptor molecules designed accordingly. For example, positioning a phosphothionate linkage or linkages between the base(s) to be added to the duplex (the predetermined bases) and the
25 non-specific part of the adaptors can be utilized (see Example 3) to permit an exonuclease to remove all but the predetermined bases.

30 The embodiments of the invention permit extremely high throughput, allowing hundreds of thousands of samples to be simultaneously processed. Applications therefore include, for example, analysis of highly complex nucleic acid samples up to whole genomes, or studying many different nucleic acids from many different individuals, for example
35 when performing population or evolutionary studies or when

studying complex linkage, especially of disease-associated traits, classifying microorganism types, or when determining total specific transcriptional activity of a cell or tissue. Diagnosis based on small percentages of
5 base differences is also facilitated.

Preferably multiple nucleic acids to be sequenced are simultaneously and independently immobilised. A preferred way is to use adaptors which are oligonucleotides
10 immobilised on beads or on a plate format, in particular glass beads or plates. Glass beads have the advantages that they are available in a wide range of mean diameters allowing optimum size to be selected, that conventional chemistries, especially oligonucleotide syntheses, can be
15 used to attach labels, that once reacted they can be rendered inert, and that their shape can be highly irregular (allowing easy and repeated identification by image analysis). Plates have similar chemical advantages, and offer the advantage that a high density of samples can
20 be arranged on a plate which is then a convenient format for reading in a scanning instrument.

It is generally impractical to subdivide large populations of nucleic acid fragments a sufficient number of times to
25 allow individual fragments to be immobilised on a single type of bead. A mixed population of beads, synthesised such that each bead recognises only one type of fragment, therefore has to be prepared.

30 The presence of different oligonucleotides of sufficient length on each bead allows each bead to capture a different sequence by hybridisation. Methods well known in the art, if required, can be used to covalently link the captured sequences onto the oligonucleotides. Plates, or other
35 materials in sheet format, can be derived/adapted to bind

or covalently attach samples under investigation.

5 Ligations in the predetermined base addition overall process, as in other aspects of the invention, can be effected using DNA ligase.

10 In order to synthesise many different oligonucleotides simultaneously on glass beads so that only one type of oligonucleotide is found on a given bead a cyclical process is used. This is achieved by performing on beads a separate synthesis for each of the first bases required. The products of these syntheses are then mixed together and then divided into four separate synthesis reactions, one for each of the bases to be added. This cycle is repeated
15 for as many positions as it is required to vary on the beads. A given bead can only have one combination of bases in its attached oligonucleotides because it is only ever exposed to one type of base addition per synthesis cycle. The actual order of bases is determined by the actual base additions to which a bead has been exposed. Cycles of this
20 general type have been reported for simultaneously synthesising many different peptides on beads such that each bead has a single peptide (Lan, K., S., et al Nature 354 p82-84 (1991)).

25 To ensure that the oligonucleotide on each bead hybridises to only a single unique nucleic acid sequence, many more permutations of bases on the beads would be used than would be expected to occur in the set of fragments to be
30 sequenced. Few beads would, therefore, detect a sequence in actuality. Thus, for practical purposes there would only be one type of fragment per occupied bead.

35 In relation to the kits of the invention, such kits can, of course, include other items as appropriate or desired, such

as DNA ligase or such chemicals as may be required for effectively using oligonucleotide labels. The kits can, of course, also include written instructions.

- 5 The invention also includes any of the adaptor molecules described above in connection with the predetermined base addition process, and adaptors as described above for use in the predetermined base removal process of the invention.
- 10 The invention will now be further described by reference to specific exemplifying material.

Examples

- 15 All of the oligonucleotides used in these examples are synthesised, using the A.B.I. 380B, on a 1 μ M scale or custom-synthesized commercially (Oswell Edinburgh). Synthesis is Trityl on unless modification by incorporation by biotin or an amino linker is performed. Biotin is
- 20 incorporated where required, at the final (5') position of the oligonucleotide, during the synthesis, with a biotin phosphoramidite, (DMT- Biotin-C6-Phosphoramidite, Cambridge Research Biochemicals Incorporated), in which case oligonucleotides are made Trityl off. Fluorescent primers
- 25 are made as required by incorporating amino linker at the appropriate position using Multi-Amino-C6-Phosphoramidite (Cambridge Research Biochemicals Incorporated) during synthesis. These are also made Trityl off. The actual dye is coupled later. Alternatively, the dye can be
- 30 incorporated during synthesis by using the appropriate phosphormidate able to add a fluorescent label (A.B.I.). Other modifications as required include 5' end phosphorylation or the inclusion of a phosphorothioate linkage (Stec, W.J., Zon, G., Egan, W., and Stec, B. J.
- 35 Amer. Chem. Soc. p6077-6079 (1984), Stec, W.J. and Zon, G.,

Tetrahedron Letters 25 p5275-5278 (1984), Stec, W.J. and Zon, G., J. Chromatography 326 p263-280 (1985)).

Phosphorylation is either chemical during synthesis, through the use of 5' Phosphate-ON (Cambridge Research Biochemicals Inc.) or enzymatic. Enzymatic phosphorylation is performed post synthesis and purification. Care is taken to ensure all traces of ammonia are removed otherwise enzymatic phosphorylation is inhibited. The additional use of a Biogel spin column below except with Tris HCl pH7.5@24°C, 1mM EDTA as running buffer is one means of ensuring ammonia removal. Enzymatic phosphorylation is performed for 30 minutes at 37°C in a 25ul reaction using 0.5 ug of oligonucleotide, 10 units of T4 polynucleotide kinase in 1mM adenosine triphosphate, 10mM magnesium chloride, 1mM dithiothreitol, 10mM Tris-HCl pH 7.5 @24°C. Purification is by extracting twice with an equal volume of phenol/chloroform 1:1 and passing through a Biogel P6 DSG resin spin column (see example 1) for which the buffer is TEA : 100mM triethylamine acetate pH7@25°C. Oligonucleotide in the eluate is dried in an aquavac for 2 hours at 50°C and redissolved in water for use.

All oligonucleotides are deprotected at 55°C, in a water bath, for 8 to 16 hours. A few drops of 3M triethylamine acetate pH 7.0@ 25°C is first added to Trityl on oligonucleotides to protect the Trityl group. Oligonucleotides are then dried in a Rotary Evaporator at 50°C or 35°C for Trityl off or Trityl on, deprotected oligonucleotides, respectively. Oligonucleotides, except those with some form of modification, are redissolved in 0.5 ml HPLC grade water.

Each 60 ug of amino-linked oligonucleotide to be dye labelled is dissolved in 80 ul of 0.5M sodium bicarbonate

buffer at pH 9.0. 6ul of the appropriate dye esters (FAM-NHS ester, JOE-NHS ester, TAMRA-NHS ester or ROX-NHS ester, all A.B.I.), are added to the oligonucleotides on which they are required and incubation performed overnight at ambient in the dark. The dye coupled oligonucleotides are passed through a spin column (see example 1) and further purified by HPLC. The spin columns in this case use 100mM TEA pH7.0@25°C as running buffer.

HPLC is conducted at a flow rate of 4.7 ml min⁻¹, using a Reverse Phase C18 Semi-prep column 5 u, 25cm x1cm (Beckman Ultrasphere), Buffer B (70 % acetonitrile) and buffer A (100 mM triethylamine acetate pH 7.0). Oligonucleotide are filtered using a 0.22 uM filter, injected into the HPLC and purified according to the appropriate gradient in Table 1.

The largest peak (eluting between ca. 9 and 11 minutes) comprises the required oligonucleotide. The eluates are dried in the rotary evaporator at 50°C, and redissolved in 200 ul of HPLC grade water. Biotinylated oligonucleotides are now ready for use. Trityl on oligonucleotides are detritylated by adding glacial acetic acid to 80 % and incubating for 20 minutes at ambient. An equal volume of absolute ethanol is added to the detritylated oligonucleotide which are then dried by rotary evaporation at 50°C. They are further purified by redissolving in 400 ul of HPLC grade water, and then precipitating for 30 minutes at room temperature by adding 40 ul of 3M sodium acetate pH 5.4 and 1000 ul of absolute ethanol. The pellet is collected in a microfuge at full speed for 20 minutes, dried at 37°C and redissolved in 200 ul of water. It is then ready for use.

<u>Trityl on</u>		<u>Biotinylated</u>		<u>Dye Labelled</u>	
<u>Oligonucleotides</u>		<u>Oligonucleotides</u>		<u>Oligonucleotides</u>	
<u>% B</u>	<u>Duration</u>	<u>% B</u>	<u>Duration</u>	<u>% B</u>	<u>Duration</u>
	(Minutes)		(Minutes)		(Minutes)
15	Initial	10	Initial	15	Initial
15	3	10	2	15	2
15 to 40	5	10 to 20	5	15 to 20	2
40	8	20 to 21.2	7	20 to 28	12
40 to 95	2	21.2 to 90	2	28 to 95	2
95	2	90	1	95	1
95 to 15	1	90 to 10	3	95 to 15	3
15	end	10	end	15	end

Example 1

5 Base Removal Sequence Analysis of the 1138 base pair NdeI to BsaI Restriction fragment of pBR322, using solid phase capture.

10 There is a single site for the restriction endonuclease BsaI in the plasmid pBR322 at position 3429, Sutcliffe, J. G. Cold Spring Harbor Symp. Quant. Biol. (1978), p77-90. The recognition and cleavage by BsaI is

5'....GGTCTC(N)₁
3'....CCAGAG(N)₅

15 Its action on pBR322 therefore leaves a single-strand extension of 5' ACCG in the direction of the recognition site and 5' CCGT in the opposite direction.

20 This provides an opportunity to demonstrate the principles described in the sequencing process. NdeI also cleaves pBR322 once at position 2295. Of the two fragments produced from pBR322 by a BsaI/NdeI double digest, the BsaI created end of the fragment which lacks the BsaI recognition site can be immobilised to a solid phase and
25 analysed by the sequencing process from the NdeI cut end.

30 Each 1µg of pBR322 used is digested to completion by 5 units of BsaI by incubation for 1 hour at 55°C in a 25 µl reaction volume containing Restriction buffer : 50 mM potassium acetate, 20 mM Tris acetate, 10 mM magnesium acetate, 1 mM dithiothreitol pH 7.9 @ 24°C. The reaction is cooled to 37°C and 10 units of NdeI are added to complete the double digestion by a further 1 hour incubation.

35 DNA is purified from the resultant mixture by extracting

twice with an equal volume of phenol/chloroform 1:1, and then passing through a Biogel P6 DSG resin spin column, containing TE: Tris-HCl pH7.5, 1mM EDTA. The unspun column has dimensions 1.5 cm high and radius 0.4cm. Spinning is performed for 2.5 minutes at 2200 r.p.m in a Clinical Centifuge with a rotor radius of 145 mm.

The end to be joined to the solid phase is ligated to a biotinylated oligonucleotide adaptor which lacks a BsaI site :

5' Biotin GAACAGTCCACCTGTGT
3'.....CTTGTCAGGTGGACACAGCCA..Phosphate 5'

This adaptors the BsaI produced end of the pBR322 fragment which lacks the BsaI recognition site. Simultaneously, the NdeI ends are ligated to a non biotinylated adaptor which contains a BsaI site in an appropriate configuration for being removed so as to leave ends which can be analysed by the reporter adaptors :

5'...TTGACAGGTGCACACGGACGGTCTCCCA
3'...AACTGTCCACGTGTGCCTGCCAGAGGGTAT..Phosphate 5'.

This adaptor also inhibits the NdeI produced ends from religating back together.

The ligation reaction is performed using the fragments purified above in 50ul of ligation buffer produced by adjusting the magnesium chloride to 10mM, dithiothreitol to 1mM, adenosine triphosphate to 1 mM, sodium chloride to 50 mM and Tris-HCl to 20mM pH 7.5 @ 24°C. 2.5 units of T4 DNA Ligase and 200 pmoles of each of the adaptors are added and the reaction performed at 16°C for 16 hours.

The ligated material is purified from the resultant mixture by extracting with an equal volume of phenol/chloroform 1:1, and then passing it according to the manufacturers instructions, through a Sephacryl S-400 Microspin column HR (Pharmacia), containing Restriction buffer less magnesium acetate. The unspun column has dimensions ca. 1.5 cm high and radius 0.4cm. Spinning is performed for 2 minutes at 1850 r.p.m in a Clinical Centifuge with a rotor radius of 145 mm.

10

Magnesium acetate is added to 10mM. 10 units of BsaI are added and incubation performed at 55°C for 1 hour. This cleaves the adaptor with the BsaI site from the fragment to be analysed leaving the latter with 5' CATA single-strand extension.

15

The fragment to be analysed is next immobilised by binding to a streptavidin coated magnetic bead solid phase (Dynabeads M-280 Streptavidin, Dynal). The beads are gently resuspended and 20 ul of suspension removed to a 0.5 ml microfuge tube. Beads in the suspension are washed as follows. First they are sedimented by placing the tube in a Magnetic Particle Concentrator (MPC-E, Dynal) and the supernatant carefully removed. The tube is removed from the magnet and the beads gently resuspended in 40 ul of Binding/Washing buffer : 10 mM Tris-HCl pH 7.5@25°C, 1 mM EDTA, 2 M sodium chloride. Washing is repeated twice more. 20 ul of Binding/Washing buffer is used to resuspend the beads after the final wash. These are then added to the restriction digestion above and the new suspension placed at 28°C for 30 minutes with occasional gentle mixing to allow the biotin to bind to the beads.

20

25

30

The bead bound fragment is then washed 5 times as above except that the final resuspension is in 40 ul of ligation

35

buffer (above). 200 pmoles of each of the reporter adaptors and 2.5 units of T4 DNA ligase are then added to allow those with specificity to the end of the immobilised fragment to ligate to the end of that fragment.

5

The four reporter adaptors are separately synthesised and purified as described above, according to the format :

5'..Phosphate $XN_4N_4N_4GAGACCGAACAGTCCACCTGTGTC$ ACTG-Dye(n)-
10 T

where X is one of the four bases A, C, G or T with a different base in each case and Dye(n) is one of the dyes FAM, JOE, TAMRA or ROX with each dye corresponding to only one of the bases at position X. The A specific reporter adaptor is labelled with JOE whose fluorescence is detected through a filter with centre band of 560nm, the C specific reporter is labelled with FAM whose fluorescence is detected through a filter with centre band of 531nm, the G specific reporter is labelled with TAMRA whose fluorescence is detected through a filter with centre band of 580nm, while the T specific reporter is labelled with ROX whose fluorescence is detected through a filter with centre band of 610nm. The reporter adaptors are mixed in equal proportions and then equimolar amounts of the reporter adaptor mixture and the complementary oligonucleotide :

3'..CTCTGGCTTGTCAGGTGGACACAGTGAC

30 are also mixed together.

Ligation is allowed to proceed for 6 hours at 16°C, and the unligated material removed by washing the beads 5 times using Washing/Binding buffer as described above except that the final resuspension is in 40 ul of Restriction buffer.

35

- 10 units of BsaI are added and incubation performed at 55°C for 1 hour with occasional gentle mixing to remove the reporter adapter and one base from the immobilised fragment. The fragments on the beads are washed in readiness for another round of ligation to the reporter adaptor as described above, except that the reporter adaptor found in the first supernatant is purified.
- Purification of the reporter adaptor is by extraction with an equal volume of phenol/chloroform and then passing through a Biogel spin column as described above except that the spin column buffer contains 100mM triethylamine acetate pH7@25°C. The eluate containing the released reporter is dried for 2 hours at 50°C in an aquavac and the adaptor redissolved in 3.5 ul of 1:1 formamide/ 50mM EDTA containing a visible amount of Dextran Blue and stored at 4°C until analysed.
- 5 further cycles of ligation of the reporter adaptors, washing, cleavage by BsaI, washing and purification of the reporter adaptor removed into the supernatant by cleavage, all as described above, are performed.
- Each of the reporter adaptor samples in formamide are analysed using an ABI model 373A DNA sequencing system. The samples are heated for 2 minutes at 90°C, placed on ice and then loaded onto a Base Sprinter gel, ran according to the manufacturers instructions. Concentration of pooled samples subject to the same treatment is performed or dilution is performed as required to gain the optimum signal strength using the DNA sequencing system. Samples are pooled by redissolving in the same aliquot of formamide/EDTA above while dilution, if necessary to obtain optimum signal strength, is also in the formamide. M13mp18

sequenced by the manufacturers dye primer chemistry according to the manufacturers instructions and the unused reporter adaptors are separately, simultaneously analysed as controls.

5

All of the reporter adaptors migrate at a rate equivalent to a 34 base sequence, allowing for the differences in mobilities imparted by the different dyes used. However, the wavelength at which they fluoresce is according to which reporter adaptor was able to ligate to the immobilised fragment during a given cycle. The first reporter removed by BsaI is detected through the 610nm filter indicating that T on the reporter ligates opposite A on the immobilised fragment. The second reporter removed is detected through the 560nm filter indicating that A on the reporter ligates opposite T on the immobilised fragment and that BsaI removes with the first reporter the A which is detected on the immobilised fragment by the previous reporter. The remaining reporters are detected through the 531, 580, 531 and 531nm filters respectively in the order in which they are removed corresponding to C,G,C,C the remaining order of bases complementary to the bases removed at the end of the immobilised fragment sequenced. The full sequence at the end of the fragment is therefore 5' A T G C G G as predicted by Sutcliffe (ref. above), starting 3 bases from the 5' end which is the position of the first BsaI cleavage made possible by the original adaptor.

10

15

20

25

Example 2

30

Base Removal Sequence Analysis of the 375 base pair EcoRI to BamHI Restriction fragment of pBR322.

35

As in example 1, advantage is taken of unique sites for restriction endonucleases in the plasmid pBR322, in this

case for EcoRI and BamHI at position 4363/0 and 375 respectively, to demonstrate the principles described in the sequencing process, Sutcliffe, J. G. Cold Spring Harbor Symp. Quant. Biol. (1978), p77-90.

5

Each 1ug of pBR322 used is digested to completion by 5 units each of EcoRI and BamHI by incubation for 2 hours at 37°C in a 25 ul reaction volume containing Restriction buffer: 50 mM potassium acetate, 20 mM Tris acetate, 10 mM magnesium acetate, 1 mM dithiothreitol pH 7.9 @ 24°C.

10

The 375 base pair fragment is purified from the resultant mixture by extracting with an equal volume of phenol/chloroform 1:1, and then passing it through a Sephacryl S-1000 column (Pharmacia) run according to gel filtration conditions. The column dimensions are radius 0.4cm and height 5cm. The running buffer is TE : Tris-HCl pH 7.5@24°C, 1mM EDTA plus the addition of sodium chloride to 50mM and the capacity is >5ug. 100ul fractions are collected and 5 ul samples from each fraction analysed by agarose gel electrophoresis (Sambrook, J., Fritsch, E.F. and Maniatis, T. ed (1989). "Molecular Cloning". Cold Spring Harbor Laboratory Press, New York) for the presence of the required fragment. Peak containing fractions are pooled, avoiding the larger fragment present and the DNA precipitated for 30 minutes at room temperature by adding 1/10th volume of 3M sodium acetate pH 5.4 and 2.5 volumes of absolute ethanol. The pellet is collected in a microfuge at full speed for 20 minutes, washed once with 70% ethanol and dried at 37°C. The pellet is then redissolved for use at 0.5 ug ul⁻¹ in TE.

15

20

25

30

35

The EcoRI end to be sequenced is ligated to an adaptor which contains a BsaI site in an appropriate configuration for being removed so as to leave ends which can be analysed

by the reporter adaptors :

5'...TTGACAGGTGCACACGGACGGTCTCCCA

3'...AACTGTCCACGTGTGCCTGCCAGAGGGTTTAA..Phosphate

5

Simultaneously, the BamHI end is ligated to an adaptor which lacks a BsaI site :

5' GAACAGTCCACCTGTGT

10 3'..CTTGTCAGGTGGACACACTAG..Phosphate 5'

The adaptors also inhibit the BamHI and EcoRI produced ends from religating back together.

15 The ligation reaction is performed using the fragment purified above in a 50ul reaction volume containing 2ug of fragment with the addition of magnesium chloride to 10mM, dithiothreitol to 1mM, adenosine triphosphate to 1 mM, sodium chloride to 50 mM and Tris-HCl to 20mM pH 7.5 @ 24°C,
20 producing ligation buffer. 0.25 units of T4 DNA Ligase and 2 pmoles of each of the adaptors are added and the reaction performed at 16°C for 16 hours.

25 The ligated fragment is purified from the resultant mixture by extracting with an equal volume of phenol/chloroform 1:1, and then passing it according to the manufacturers instructions, through a Sephacryl S-400 Microspin column HR (Pharmacia), containing Restriction buffer above but lacking magnesium. The unspun column has dimensions ca.
30 1.5 cm high and radius 0.4cm. Spinning is performed for 2 minutes at 1850 r.p.m in a Clinical Centifuge with a rotor radius of 145 mm.

35 Magnesium acetate is added to 10 mM to the eluate. 10 units of BsaI are added and incubation performed at 55°C for

1 hour. This cleaves the adaptor from the fragment to be immobilised leaving the fragment with a 5' CAAA single-stranded extension.

5 The newly digested material is purified by extracting with an equal volume of phenol/chloroform 1:1, and then passing it according to the manufacturers instructions, through a Sephacryl S-400 Microspin column HR (Pharmacia) as described above but containing ligation buffer.

10

200 pmoles of each of the reporter adaptors and 0.25 units of T4 DNA ligase are then added to allow those with specificity to the BsaI cut end of the purified fragment to ligate to the end of that fragment.

15

The four reporter adaptors are seperately synthesised and purified as described above, according to the format :

20

5'..Phosphate $XN_4N_4N_4GAGACCGAACAGTCCACCTGTGTC$ ACTG-Dye(n)-
T

25

where X is one of the four bases A, C, G or T with a different base in each case and Dye(n) is one of the dyes FAM, JOE, TAMRA or ROX with each dye corresponding to only one of the bases at position X. The A specific reporter adaptor is labelled with JOE whose fluorecence is detected through a filter with centre band of 560nm, the C specific reporter is labelled with FAM whose fluorecence is detected through a filter with centre band of 531nm, the G specific reporter is labelled with TAMRA whose fluorecence is detected through a filter with centre band of 580nm, while the T specific reporter is labelled with ROX whose fluorecence is detected through a filter with centre band of 610nm. The reporter adaptors are mixed in equal proportions and then equimolar amounts of the reporter

35

adaptor mixture and the complementary oligonucleotide :

3'...CTCTGGCTTGTCAGGTGGACACAGTGAC

5 are also mixed together.

Ligation is allowed to proceed for 6 hours at 16°C, and the unligated material removed by extracting with an equal volume of phenol/chloroform 1:1, and then passing it according to the manufacturers instructions, through a
10 Sephacryl S-400 Microspin column HR (Pharmacia) as described above but containing Restriction buffer.

10 units of BsaI are added and incubation performed at 55°C
15 for 1 hour to remove the reporter adaptor and one base from the immobilised fragment. The digested fragment is purified in readiness for another round of ligation to the reporter adaptor by extracting with an equal volume of phenol/chloroform 1:1, and then passing it according to the
20 manufacturers instructions, through a Sephacryl S-400 Microspin column HR (Pharmacia) as described above but containing 100mM triethylamine acetate pH7.0@24°C (TEA). Addition of fresh 50 ul aliquots of TEA to the microspin column and centrifuging between each addition as above is
25 continued (1 to 4 more times) to elute the reporter cleaved from the fragment. The reporter and the fragment are separately dried in an aquavac at 50°C for 2 hours. The reporter is redissolved in 3.5 ul of 1:1 formamide/ 50mM EDTA containing a visible amount of Dextran Blue and stored
30 at 4°C until analysed.

The fragment is dissolved in 50 ul of ligation buffer and subjected to 5 further cycles of ligation of the reporter adaptors, purification, cleavage by BsaI, purification of
35 the fragment and purification of the reporter adaptor

removed by cleavage, all as described above.

Each of the reporter adaptor samples in formamide are analysed using an ABI model 373A DNA sequencing system. The samples are heated for 2 minutes at 90°C, placed on ice and then loaded onto a Base Sprinter gel, ran according to the manufacturers instructions. Concentration of pooled samples subject to the same treatment is performed or dilution is performed as required to gain the optimum signal strength using the DNA sequencing system. Samples are pooled by redissolving in the same aliquot of formamide/EDTA above while dilution is also in the formamide. M13mp18 sequenced by the manufacturers dye primer chemistry according to the manufacturers instructions and the unused reporter adaptors are separately, simultaneously analysed as controls.

All of the reporter adaptors migrate at a rate equivalent to a 34 base sequence, allowing for the differences in mobilities imparted by the different dyes used. However, the wavelength at which they fluoresce is according to which reporter adaptor was able to ligate to the immobilised fragment during a given cycle. The first reporter removed by BsaI is detected through the 610nm filter indicating that T on the reporter ligates opposite A on the immobilised fragment. The second reporter removed is detected through the 560nm filter indicating that A on the reporter ligates opposite T on the immobilised fragment and that BsaI removes with the first reporter the A which is detected on the immobilised fragment by the previous reporter. The remaining reporters are detected through the 560, 580, 560 and 580nm filters respectively in the order in which they are removed corresponding to A,G,A,G the remaining order of bases complementary to the bases removed at the end of the immobilised fragment sequenced. The full



sequence at the end of the fragment is therefore 5' A T T C T C as predicted by Sutcliffe (ref. above), starting 2 bases from the 5' end which is the position of the first BsaI cleavage made possible by the original adaptor.

5

Example 3

5' to 3' sequence analysis of M13mp18

10 M13 mp18 is a single-stranded DNA of known sequence (Messing, J., Methods in Enzymology 101 (Part C) Recombinant DNA p20-78 (1983) Wu, R., and Moldave, K. (eds). Academic Press, New York). It is therefore a
15 suitable substrate for demonstrating the process of sequencing using reporter adaptors which add bases during each sequencing cycle.

M13mp18 single-stranded DNA is annealed to the forward
20 primer :

3' TGACCGGCAGCAAAATG.

25 Each ug of M13 DNA is added to 2 pmoles of primer in 20 ul of Annealing buffer : 10mM Tris-HCl pH7.5@24°C, 50mM sodium chloride. The reaction is heated to 95°C for 2 minutes and then cooled to 55°C for 30 minutes.

30 The annealed template/primer is ligated to the reporter adaptors. Each reporter adaptor is separately synthesised and purified. The first 15 of the oligonucleotides are tagged according to the Plex Tags (Millipore) :

35	Tag_01	ATATATATCCCATAATCCACnnnnnAsA 5' phosphate
	Tag_02	CATTCTATTCTAAATCACTCnnnnnAsC 5' phosphate

	Tag_03	TCTTCAATTACATCCCAACCnnnnnAsG	5' phosphate
	Tag_04	TCAAATCACCTACCCACAACnnnnnAsT	5' phosphate
	Tag_05	AAACACTAAACTCAATACACnnnnnCsA	5' phosphate
	Tag_06	CATCATTCCAAACAACAATCnnnnnCsC	5' phosphate
5	Tag_07	CTATATCCAACCATCTTCCCnnnnnCsG	5' phosphate
	Tag_08	CCCACACTATTTTCACATTCCnnnnnCsT	5' phosphate
	Tag_09	AAAAACCCTTAATCAAAAACnnnnnGsA	5' phosphate
	Tag_10	TCATCCCAACCAACACCAACnnnnnGsC	5' phosphate
	Tag_11	ACTCATATAACTACTAATCCnnnnnGsG	5' phosphate
10	Tag_12	AACACAATTTACAACCAAAACnnnnnGsT	5' phosphate
	Tag_13	CACTATTCATCTCAACCAACnnnnnTsA	5' phosphate
	Tag_14	TCACACTCCAAATTTATAACnnnnnTsC	5' phosphate
	Tag_15	TCCCAAATCCAATATAATACnnnnnTsG	5' phosphate
	Tag_16	AAGGAAAATGTGGTGGAATGnnnnnTsT	5' phosphate

15

n corresponds to all four bases at a given position and s corresponds to a phosphorothioate linkage.

20 The annealing reaction is adjusted to Ligation buffer by adding Tris-HCl pH7.5@24°C to 20mM, sodium chloride to 50mM, dithiothreitol to 1mM, magnesium chloride to 10mM and adenosine triphosphate to 1mM.

25 The reporter adaptors are mixed in equimolar proportions and then the mixture added to the ligation reaction. The reporter adaptor mixture is added in a molar ratio of 100:1 of M13mp18 DNA.

30 0.25 units of T4 DNA ligase is added and incubation performed for 6 to 16 hours at 16°C.

35 M13 plus ligated reporter adaptor are purified from the ligation mixture using the LacZ Vector Purification Kit (Dynal) according to the manufacturers instructions except that : the ligation reaction is the starting point rather

than a phage supernatant, 100 μ l of beads suspension (Dynabeads M-280 Streptavidin, Dynal) are used with 25pmoles of custom prepared oligonucleotide which is identical to the oligonucleotide on the supplied beads except that the three 3' most nucleotides are joined by phosphorothioate linkages so that they are exonuclease resistant, four washes are performed and 20 μ l of elution buffer are used. Eluate equivalent to 100ng of M13mp18 DNA is removed as a sample to determine which reporter adaptor ligated.

The remainder of the eluate is prepared for further rounds of reporter addition. T4 DNA polymerase is used to remove the TAG, so that the remainder of the reporter can be subject to the action of Exonuclease III. The eluate is adjusted to Pol/Exo buffer by the addition of Tris-HCl pH7.5@24°C to 20mM, magnesium chloride to 10mM, dithiothreitol to 1mM and sodium chloride to 50mM. The new mixture is divided into four equal aliquots. To each is added three different deoxyribonucleotides to 0.1mM each. The deoxyribonucleotides are added such that each reaction misses a different base. This prevents extensive polymerisation from occurring once the TAG has been removed and also covers the possibility that entirely one type of base could be found in the double-stranded region between the TAG and the specific bases. By dividing the reaction into four different types, when the aforementioned situation does arise, loss of the double stranded region will only occur for 25% of the remaining eluate. 1 unit of T4 DNA polymerase is added and incubation performed at 37°C for 30 minutes. DNA is purified from the reaction using the LacZ Vector Purification Kit as described above, except that no sample is removed.

Exonuclease III is used to remove from the remainder of the

M13 DNA, the remainder of the reporter adaptor up to the phosphorothioate linkage. Two additional bases are therefore left on the primer. The eluate is adjusted to Exonuclease III buffer by the addition of Tris-HCl pH8.0@24°C to 50mM, magnesium chloride to 5mM and 2-mercaptoethanol to 10mM. 0.1 unit of exonuclease III is added and incubation is performed at 37°C for 10 minutes. DNA is purified from the reaction mixture using the LacZ Vector Purification Kit as described above, except that no sample is removed.

5 further rounds of ligation to the reporters, purification, removal of sample for analysis of the TAG present, treatment with T4 DNA polymerase, purification, treatment with exonuclease III and purification are performed, ending with sampling during the final cycle.

To examine the reporters present at each cycle they are divided into 8 equal proportions, spotted individually onto 8 Nylon membranes with one of each sample per membrane. 5ng of each of the original reporter adaptors are also spotted separately onto each membrane as a control. The membranes are probed by hybridisation, washed and finally detected by autoradiography, all methods including spotting are according to standard procedures (Sambrook, J., Fritsch, E.F. and Maniatis, T. ed (1989). "Molecular Cloning". Cold Spring Harbor Laboratory Press, New York).

Oligonucleotides complementary to the last 3' most sequences (Plex Tags) of the reporter adaptors are used as probes. Each oligonucleotide is synthesised separately and labelled by T4 polynucleotide kinase with gamma ³²P adenosine triphosphate.

The membranes are probed as follows :

First membrane with the oligonucleotide complementary to Tag_07

5 Second membrane with the oligonucleotide complementary to Tag_02

Third membrane with the oligonucleotide complementary to Tag_09

Fourth membrane with the oligonucleotide complementary to Tag_14

10 Fifth membrane with the oligonucleotide complementary to Tag_12

Sixth membrane with the oligonucleotide complementary to Tag_02

15 Seventh membrane with the oligonucleotides complementary to Tags that have not already been used. The specific activity of each oligonucleotide is maintained the same as in the previous probings so that in this case, eleven times more probe is used overall.

20 Eighth membrane with the oligonucleotides complementary to Tag_02, Tag_07, Tag_09, Tag_12, and Tag_14. Again, the specific activity of the individual probes are maintained so that overall five times more probe is used.

25 The positions of Tag_07 and the first sample are primarily labelled on the first membrane indicating that the reporter adaptor corresponding to CG was incorporated during the first ligation. The positions of Tag_02 and the second and sixth samples are primarily labelled on the second membrane indicating that the reporter adaptor corresponding to AC

30 was incorporated during the second and sixth ligations. Furthermore, the 3' end of the primer was no longer the same after the first exonuclease treatment. Similarly, the positions of Tag_09 and the third sample, Tag_14 and the fourth sample, Tag_12 and the fifth sample and Tag_02 and

35 the second and sixth samples are labelled on the third,

fourth, fifth and sixth membranes, respectively. This indicates that the reporter adaptors corresponding to GA, TC, GT, and AC were incorporated respectively, one per each cycle from the third cycle. It also suggests that the
5 sequence is 5' GCCAAGCTTGCA from the 3' end of the primer and that the two bases at the 5' end of each Tag were left behind following the exonuclease treatment during the cycle that the TAG was incorporated.

10 The final two membranes serve as a control to demonstrate that the only oligonucleotides which will detect the samples and the TAGs are those which are expected to be complementary to them.

15 As will be appreciated from the above, included in the present inventive concept is the idea that beads, which may be randomly chosen, each with their own unique oligonucleotide attached can be used for ordering nucleic acids for sequencing purposes. The use of irregular beads
20 enables benefit to be taken from the individual optical signature which each such bead possesses. The ability to correlate between nucleic acids and particular unique beads obviates the need for more formal arrays of nucleic acids. The invention includes this concept and uses thereof.

25 Of course, the beads are readily available and standard chemical techniques known to those in the art can be used for linking with oligonucleotides.

30 Example 4

In relation to this Example, the accompanying Figure 3(a) is an electropherogram of BamHI to EcoRI and BamHI to EagI fragments of pBR322, previously labelled during a first
35 cycle of ligation to reporter adaptors, and showing



expected specific labelling by the TAMRA reporter. Figure 3(b) is an electropherogram of BamH1 to EcoR1 and BamH1 to Eag1 fragments of pBR322, previously labelled during a first cycle of ligation to reporter adaptors, and then cut by Bsa1, showing expected removal by the endonuclease of the specific labelling by the TAMRA reporter.

45 µg of pBR332 per digest were cut to completion by 450 units each of EcoR1 and Eag1 for 2 hrs at 37°C in 450 µl of 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl₂, 1 mM DTT pH7.9 at 25°C. 2 µl of the digest were examined by agarose gel electrophoresis to confirm digestion. The fragments produced were purified by extracting with an equal volume of 1:1 phenol/chloroform twice followed by an equal volume of chloroform, the aqueous phase being retained in each case. Two minutes microcentrifugation were used to separate the phases which were mixed initially by vortexing for 30 seconds.

The DNA was precipitated by adding 1/10 volume of 3M Na acetate pH 5.3 and 2.5 volumes of the new volume of 100% ethanol. After about 30 minutes at -20°C the precipitate was collected by microcentrifugation at 15000 xg for 15 minutes. The supernatant was discarded and the pellet washed with 1 ml of 70% ethanol. Centrifugation was repeated for 5 minutes and the supernatant again discarded. Residual liquid was removed using a Gilson tip after a brief microcentrifugation to collect it at the bottom of the tube. Care was taken to avoid removing the pellet at any stage. The pellet was dried at 37°C for 10 minutes and then re-dissolved in 92 µl of TE: Tris-HCl 10 mM pH 7.5 at 20°C and 1 mM EDTA. 2µl were examined by agarose gel electrophoresis to check recovery. It was necessary to vortex the TE throughout the tube which contained the pellet to ensure that all traces became dissolved.

Two oligonucleotide pairs were prepared as described previously for the purpose of blocking the majority of the EcoR1 and Eag1 cohesive ends:

5

5' AATTCGGAGTGAAAGCG 3'
5' GCCTCACTTTCG 5'

and

10

5' GGCCGGCCTGACTCT 3'
 CCGGACTGAGAG 5'

respectively.

15 pmoles of each of the blocking oligonucleotides were ligated to the cut and purified pBR322 in a 360 μ l reaction at 22°C for 1.5 hours containing 3.6 units of T4 DNA ligase, 10 mM Tris-HCl pH7.5 @ 22°C, 50 mM BaCl₂, 10 mM MgCl₂, 1 mM DTT, 1 mM ATP. The ligase was added last and the reaction heated to 65°C and then cooled to ambient to aneal the oligonucleotides prior to its addition. 1/60 of the reaction was prepared as a control without the oligonucleotides and analysed by agarose gel electrophoresis alongside 1/60 of the main reaction to confirm that concatamerisation could occur in the absence of the blocking oligonucleotides. After ligation, DNA was purified from the main reaction by extracting twice with phenol/chloroform as described above and then divided equally between 4 S-400 MicroSpin columns (Pharmacia), run according to the manufacturers instructions at 1850 cpm for 2 minutes in a clinical centrifuge with a rotor radius of 145 mm. The resultant eluates were pooled and the 939 base pair EcoR1 to Eag1 fragment cut by 240 units BamH1 at 37°C for 1 hour, in a 600 μ l reaction containing NaCl and MgCl₂ added to 50 mM and 10 mM respectively. This had the effect of creating two BamH1 cohesive ends on different fragments whose opposite ends could no longer participate in

ligation.

1/30 of the reaction was set up without BamH1 as an uncut control and compared to 1/30 of the digest by agarose gel electrophoresis to confirm that bands of 375 and 564 base pairs were produced from the original 939 base pair fragment. The main reaction was purified by phenol extraction and ethanol precipitation and re-dissolved in 90 μ l TE as described above, except that the 70% ethanol wash was omitted. Low molecular weight material, especially oligonucleotides were further removed by passing the new solution through a sephacryl S-1000 (Pharmacia) column run at 15-20 cm of water pressure. The column had dimensions 5 cm high and 1 cm diameter. Peak fractions were determined by agarose gel electrophoresis, pooled and ligated overnight to the labelled reporter adaptors, to commence a first cycle of ligation of reporters to be followed by cutting. Had the oligonucleotides not been removed, they would have competed for ligation to the labelled reporter adaptors. The reporter adaptors were as described in Examples 1 and 2. It had been empirically determined that a ratio of between 0.3 to 1 pmole of digested pBR322 to between 64 to 320 pmoles of each of the reporter adaptors, in a 100 μ l ligation gave specific labelling of the pBR322 fragments as determined by a fluorescence gel reader. This probably reflected the fact that too low a concentration of adaptors failed to block concatamerisation of the pBR322, while too high a concentration of adaptors reduced the yield of labelled product, probably because the adaptors have a 5' phosphate and are therefore able to ligate to each other thus lowering their effective concentration. Alternative strategies would utilise unphosphorylated adaptors to eliminate the latter effect. Should the nicked DNA which resulted between ligation of such adaptors and the fragment

of interest not be tolerated for some reason by the process, a kinase plus ligation step could be used to repair the nick after removal of the reporter adaptors.

5 Ligation was conducted in a 2400 μ l volume containing 1875 pmoles of each reporter adaptor, 10 mM Tris-HCl pH 7.5 at 22°C, 10 mM $MgCl_2$, 50mM NaCl, 1 mM DTT, 1 mM ATP and 24 units of T4 DNA ligase for 16 hours at 16°C. The ligase was added last and prior to its addition the reaction was
10 heated to 65°C for 5 minutes then cooled to ambient to aneal the oligonucleotides. A control was set up from other equivalent reactions containing amounts corresponding to 1/10 of the S-1000 eluate (ligase control). Controls from other equivalent reactions were also set up containing
15 amounts corresponding to 1/10 of the S-1000 eluate. In these, the same final concentrations of reporter oligonucleotide were used but were made but were made up entirely of only one of the reporters i.e. 4 x the original concentration of a given reporter was used and none of the
20 other reporters.

After ligation, fragments in each reaction were purified by extraction twice with phenol/chloroform and ethanol precipitation as described above except that the 70%
25 ethanol wash was omitted. The control reactions were re-dissolved in 100 μ l of TE each and the main reaction in 205 μ l of TE. 5 μ l of the 205 μ l were examined on an agarose gel to check recovery. The bulk of the reporter adaptors were removed by passing through a SizeSep 400 Spin Column
30 (Pharmacia) run according to the manufacturers instructions at 1550 rpm for 2 mins in a 145 mm radius rotor. 100 μ l were loaded on each column so that two columns were required for the main reaction. The column dimensions were approximately 0.8 cm diameter and 3 cm high. Columns was
35 equilibrated before use with 8 mls of TE + 50 mM NaCl,

flowing under gravity.

Half of the eluate from the control reactions and all but 1/12 of the total pooled eluate from the main reaction were digested by Bsa1 to remove the reporter adaptors, and the end base of the fragment ligated to the reporters. Digests were performed in Bsa1 buffer (NEB) at 55°C for 1.5 hrs containing 20 units per 100 µl of Bsa1. Digests were performed in approximately twice the volume originally added to the columns. Bsa1 was added last and 1/40 of the reaction was sampled prior to adding the enzyme to examine on an agarose gel as an uncut control. Similarly 1/40 of the reaction was also examined after the reaction to confirm that digestion had occurred. Bsa1 cuts the 3323 Eag1 to EcoR1 fragment of pBR322 to give a 929 base fragment and a 2494 base fragment. These fragments appear to be slightly larger because of the adaptors added to the EcoR1 and Eag1 ends.

The digest from the control reactions and 1/12 of the digest from the main reaction were purified by extraction twice with phenol/chloroform and ethanol precipitation as described above, except that the 70% ethanol wash was omitted. The undigested samples from the control reaction and the sample corresponding to 1/12 of the undigested main reaction were similarly purified, except that the phenol/chloroform extractions were also omitted. The precipitated samples were retained for analysis by a fluorescent gel reader, see below.

The main reaction was extracted twice by phenol/chloroform as described above and further purified by passing through S-400 MicroSpin columns as described above. The remaining reaction totalled approximately 400 µl and 100 µl was used for each of four columns. This completed the first cycle

of ligation of reporters followed by cutting to expose the next base for analysis. A second cycle of ligation of adaptors then cutting was commenced. New reporters were ligated to the newly generated cohesive ends in the purified main reaction. The total eluate equalled 480 μ l. Ligation was performed as for the first main reporter ligation, with the same proportions of reactants but scaled accordingly for a final reaction volume of 600 μ l.

This ligation was purified, ethanol precipitated and the oligonucleotides removed by SizeSep 400 Spincolumns as described for the first main reporter ligation. BsaI digestion was performed as previously described except that 1/6 of the reaction was sampled as an uncut control and post digestion 1/6 of the reaction were sampled as a cut control. The two samples were purified and stored as ethanol precipitates as described for the samples after the first reporter ligation.

The remaining BsaI cut material was also purified and ligated to new reporter adaptors as previously described to commence a third cycle of ligation then cutting. Purification and BsaI digestion was performed as previously described except that half the first eluate was retained as an uncut control, and the remainder was digested by BsaI. The cut sample was purified by phenol/chloroform extraction as described and then both samples were recovered by ethanol precipitation as described above. This completed the third cycle of ligation and cutting.

It proved appropriate to take as samples increasing proportions of the main reaction during each successive cycle to allow for the losses which occurred during each cycle, particularly through the columns. Losses were most pronounced for the smaller fragments, presumable reflecting

the size-separating properties of the columns used. It would therefore be preferred in such embodiments to use larger fragments for analysis. A BsaI and EagI cut fragment of pBR322 that had their ends blocked before cutting with EcoRI would be one instance of how this could be achieved. The fragments need to be large enough to be retained during the purification but not so large that they cannot be resolved in the analysis which follows. 900 to 1800 base pairs is a suitable range. An alternative strategy was also adopted in very similar experiments. In this case large fragments were processed, and then samples were cut with a restriction endonuclease which produced smaller fragments suitable for analysis and on which the ends of interest could be found. For example, the NdeI to BsaI fragment of pBR322 was used. In this case, the BsaI produced end nearest the NdeI site was blocked prior to use of the reporter adaptors. TaqI was then used to produce fragments which were suitable for analysis from samples which had been taken during the cycling process.

The ethanol precipitates corresponding to each sample were re-dissolved in 3 μ l of TE and the 3 μ l of gel loading buffer: formamide, 50 mM EDTA plus visible amount of Dextran Blue. Each sample was analysed by electrophoresis using the A.B.I. 373A according to the manufacturers instructions. Short plates (6 cm well to read) were used. Electrophoresis was at 30 watts for 3.5 hours using a 6% polyacrylamide gel polymerised with 0.5% ammonium persulphate and 0.05% TEMED. The unpolymerised gel solution was prepared using 80 g urea, 24 ml 40% 29:1 Acrylamide : Bisacrylamide, 60 mls Milli Q grade water (Millipore) and 2 g mixed bed ion exchange resin. Stirring was performed for 30 minutes and then solid material removed by filtration through a 0.2 μ m Nalgene filter. 16ml TBE (108 g Tris base, 55 g Boric acid and 8.3 g Na₂EDTA

per litre) and water were added to 160 ml and degassing performed.

5 24 cm well to read (large plates) were used when greater resolution was required. Samples were diluted in gel loading buffer if signal intensities were too great. Electropherograms were scaled according to the largest peak which was usually unincorporated reporters. Dye scales were therefore reduced in height to enhance small peaks, where
10 necessary.

Filter set A was used and Rox 350, Rox 500, Rox 1000, Rox 2500 were also ran as size markers. Genescan 672 collection was run during electrophoresis and Genescan 672
15 analysis was used for analysis.

Ligation of reporter to the fragments was only observed when the correct reporters were available. When during the controls, only one labelled reporter was used with BamH1,
20 Eag1, EcoR1 cut pBR322, then labelled fragments were only observed at scan positions 850 and 1050 of the gel (depending on the actual run) which corresponded to the 375 and 564 base fragments respectively (as judged from the size markers) and only when the TAMRA reporter, (yellow)
25 was present. This corresponded to ligation of the 5' terminal G on the TAMRA reporter to the exposed BamHi cohesive end as expected so that signal could only be observed in the yellow lane.

30 No significant label was observed in any sample if ligase had not been added during the ligation reactions, confirming that ligation of the reporters was required to label the fragments.

35 During the first cycle, when all four reporter adaptors

were present, significant label was only observed in the TAMRA (yellow) lane at the positions corresponding to the 375 and 564 base fragments. This is again consistent with correct ligation of the terminal G of the TAMRA adaptor to the 375 and 564 base fragments. The other lanes were not significantly labelled at this position - see Figure 3(a).

One cycle later, the same two fragments are again labelled with TAMRA as expected because a BamHI cohesive end is GGATCC, so one base further in the 3' direction into the sequence is still on C. An additional fragment at position 1450 corresponding to the 929 BsaI to EcoRI fragment is now also observed to be labelled. This fragment is labelled with FAM (blue) as expected since the C at the 5' end of the FAM reporter should pair with the G exposed four bases in the 3' direction for the 5' end of the BsaI generated cohesive end. It is significant that in this case, where three possible ends were available, only the expected reporters found their appropriate ends. Digestion by BsaI has abolished the labelling which occurred after the first cycle as expected if this enzyme removes the reporter adaptors. Labelling in the second cycle is not simply as a result of carry over from the first cycle.

BsaI digestion after the second and third ligation of reporters also abolishes the labelling as expected if it removes the ligated reporter adaptors. The labelling observed after the third ligation of reporters is also significant because the BamHI generated ends are observed to be labelled by the JOE reporter (green) which can only arise if a further single base removal occurred during the second BsaI cutting and the expected reporter was added during the third reporter ligation. In contrast, a mixture of blue and yellow labelling are observed for the BsaI to EcoRI fragment. This is expected because during the second

Bsa1 digestion there are two possible Bsa1 sites that can mutually exclusively be used. The one contributed by the reporter results in removal of the reporter plus one base into the pBR322. The Bsa1 site contributed by the PBR322 results in removal of the reporter but no bases of pBR322 are removed. Two possible ends therefore result at the EcoR1 to Bsa1 generated end. These are differently labelled with either the FAM reporter (C) of the TAMRA reporter (G), depending on the end remaining.

Traces of dye can remain on the fragments after removal of the ligated reporters by Bsa1. This is expected because restriction endonucleases are not 100% efficient. It does not affect the method because restriction endonucleases at least 95% efficient can be selected so that small amounts of label which remain after digestion can be distinguished from the large amounts of label which are added on ligation of the reporters. The noise contributed by the small number of failures of the restriction enzyme are not expected to be a problem up to at least 20 cycles of the process.

Care has to be exercised during the phenol/chloroform extractions to remove the Bsa1. More than two phenol/chloroform extractions can be used post- Bsa1 digestion to minimise the Bsa1 "carry over". Alternatively, smaller quantities of enzyme can be used for longer time periods. As yet a further alternative, a more labile enzyme could be used.

In a similar experiment, labelling by the reporters of the small and large Nde1 to Bsa1 fragments of pBR322 were monitored at the Nde1 ends through two cycles of cutting and ligation. Samples were cut with Taq1 prior to loading onto the fluorescent gel reader to produce fragments which

could be resolved on the gel system used. Oligonucleotides were as described in Example 1.

5 In this case both the short and large NdeI to TaqI
fragments were red after the first cycle of ligation of the
four reporters, and green after the second cycle of
ligation to the reporters. The results are as expected and
consistent with only the reporter with the T specific end
ligating during the first reporter ligation and the
10 reporter with the A specific end ligating during the second
ligation and the base of pBR322 adjacent to the reporter
being removed during BsaI digestion. Also as expected, the
unblocked BsaI produced end was blue after one reporter
ligation and blue and yellow after the second reporter
15 ligation as discussed above.

Purifying fragments between cycles necessitate using large
amounts of starting material to allow for losses occurring
during purification. This in turn results in large
20 reaction volumes. This is overcome when fragments are
immobilised on a solid phase since then there is no
opportunity for the fragments to part from the process.
Only sufficient depth of reaction volume to cover the solid
phase is required. This can be equivalent to a film of
25 liquid, and therefore reaction volumes (and costs) are
lower when a solid phase is used.

Claims

1. A method of sequencing a population of double stranded nucleic acids, comprising:-

5

(a) ligating to said nucleic acids adaptors which include double stranded oligonucleotide sequence which incorporates a predetermined nuclease recognition sequence for a nuclease whose recognition site is displaced from its cleavage site, said displacement being such as to create, as a result of said ligation, cleavage sites in the resulting ligation products which, upon cleavage thereat, result in removal of a base or bases from one strand of said nucleic acids;

10

15

20

(b) cleaving ligation products from (a) with said nuclease to produce double stranded products of unequal strand length;

(c) subjecting said products from (b) to ligation with a population of adaptors which include double stranded oligonucleotide sequence having extending single strands wherein said population of adaptors includes molecules having in their extending single strands permutations, optionally all possible such permutations, of a base or bases constituting a predetermined number of bases, and wherein each permutation is provided with a respective unique and detectable label, each adaptor in said population having a nuclease recognition sequence for a nuclease whose recognition site is displaced from its cleavage site, said displacement being such as to create, as a result of the ligation of this step (c),

25

30

35

upon cleavage thereat, result in removal of a base or bases from one strand of said products from (b);

- 5 (d) separating the ligation products from (c);
- (e) cleaving the separated ligation products from (c) with the nuclease of (c) to produce a population of fragments carrying the recognition site of the
10 nuclease of (c);
- (f) either analyzing the labels carried by ligation products separated in (d), or analyzing the labels carried by fragments from (e); and
15
- (g) repeating steps (c) to (f) as often as necessary to determine the desired sequence, but with the final repeat optionally omitting step (e).
- 20 2. A method as claimed in claim 1 wherein step (a) is preceded by treatment of said population of nucleic acids with the nuclease(s) to be used in subsequent steps.
- 25 3. A method as claimed in claim 1 or claim 2 wherein the nuclease used in each step (c) is not the same as the nuclease used in step (a).
4. A method as claimed in any one of claims 1 to 3 wherein said adaptors are oligonucleotides.
30
5. A method as claimed in any one of claims 1 to 4 wherein said nucleic acids are immobilised.
- 35 6. A method as claimed in claim 5, wherein immobilisation is achieved using a flat substrate which permits the

analysis of step (f) to be performed by scanning, optionally fluorescent scanning.

5 7. A method as claimed in claim 6, wherein said substrate is a plate or film.

8. A method as claimed in any one of claims 1 to 7, wherein said adaptors include at least some having double stranded oligonucleotide sequence which incorporates at
10 least two different said nuclease recognition sequences.

9. A process for sequencing single stranded nucleic acid having or being provided with at least some known sequence, comprising:-
15

- (a) annealing an oligonucleotide primer to said known sequence immediately adjacent to the unknown sequence to be determined in said nucleic acid;
- 20 (b) subjecting the end of said oligonucleotide immediately adjacent to the unknown sequence to ligation with a population of labelled adaptors having oligonucleotide sequence including all possible permutations of a predetermined number
25 of bases positioned at the end thereof which is so-ligated, the adaptors of said population being employed simultaneously, in preselected groups, or one by one, as desired;
- 30 (c) detecting the specific adaptor from said population which was ligated in (b);
- (d) removing all of said specific ligated adaptor except for said one or more predetermined bases
35 thereby to extend the double stranded region of

the resulting product; and

5 (e) repeating steps (b) to (d) to the necessary extent to determine the unknown sequence, but with the final repeat optionally omitting step (d).

10 10. A process as claimed in claim 9 wherein said adaptors are oligonucleotides.

11. A process as claimed in claim 9 or claim 10 wherein each step (d) is facilitated by the incorporation of a phosphothionate linkage in the adaptor oligonucleotide sequence whereby an exonuclease can cleave said adaptors to
15 leave said predetermined number of bases.

12. A process as claimed in any one of claims 9 to 11 wherein said adaptors are immobilised; optionally using a flat substrate which permits the detection of step (c) by
20 scanning, e.g. fluorescent scanning.

13. The use of a nuclease having a recognition site displaced from its cleavage site in the sequencing of nucleic acid.
25

14. A kit for sequencing nucleic acid which comprises at least one nuclease having its recognition site displaced from its cleavage site and/or a population of double stranded oligonucleotides in which the strands are of
30 unequal length with one or more predetermined bases in the extending strand and with the double stranded portion including a recognition site for a nuclease having its recognition site displaced from its cleavage site.

35 15. A kit as claimed in claim 14 also incorporating

instructions for the performance of a method as defined in claim 1.

16. A kit as claimed in claim 14 or claim 15 wherein said
5 oligonucleotides include at two different said recognition sites.

17. A kit for sequencing nucleic acid comprising labelled
adaptors having single stranded oligonucleotide sequence
10 including a predetermined number of bases at an end thereof, the labels of the adaptors being specific for their respective predetermined bases.

18. A kit as claimed in claim 17 also incorporating
15 instructions for the performance of a process as defined in claim 9.

19. Adaptor molecules including double stranded
oligonucleotide sequence which incorporates a predetermined
20 nuclease recognition sequence for a nuclease whose recognition site is displaced from its cleavage site, said molecules being for use in a method as defined in claim 1.

20. Adaptor molecules as claimed in claim 19 including at
25 least two different said recognition sequences.

21. Adaptor molecules including double stranded
oligonucleotide sequence having an extending single strand
incorporating a predetermined base or bases, said molecules
30 also including a nuclease recognition sequence for a nuclease whose recognition site is displaced from its cleavage site and a label specific for the respective predetermined base(s), preferably said molecules being for use in a method as defined in claim 1.

22. Adaptor molecules as claimed in claim 21 including at least two different said recognition sequences.

5 23. Adaptor molecules comprising single stranded oligonucleotide sequence including at an end thereof a predetermined base or bases, said molecules further incorporating a label specific for the respective predetermined base(s), said molecules being for use in a method as defined in claim 9.

10

24. A method of sequencing a nucleic acid, comprising either sequentially removing bases from the sequence of the nucleic acid a predetermined number at a time, with the product remaining from of each step of predetermined base removal being ligated to a labelled adapter specific for said bases and including oligonucleotide sequence, or hybridising a primer to the nucleic acid to be sequenced and sequentially extending said primer a predetermined number of bases at a time, said added base(s) being complementary to base(s) in the nucleic acid being sequenced, and each of said base addition steps being achieved by the use of a labelled adaptor specific for said bases and including oligonucleotide sequence containing said predetermined base(s); in either case, the label of said labelled adaptor being specific for its respective predetermined base(s).

15

20

25

30

25. A method as claimed in claim 24 wherein said labelled adaptors are oligonucleotides.

26. A method as claimed in claim 24 or claim 25 wherein said adaptors are immobilised and said method proceeds by sequentially extending said primer.

35

27. A method as claimed in claim 24 or claim 25 wherein

said method proceeds by sequentially removing bases from said nucleic acid being sequenced and before the first step of base removal said nucleic acid is subjected to the action of a restriction endonuclease.

5

28. A method as claimed in any one of claims 24 to 27 wherein a population of nucleic acids is sequenced simultaneously.

10

29. A method as claimed in claim 28 wherein said population of nucleic acids is immobilised.

15

30. A method of ordering nucleic acids by the use of irregularly shaped beads or other irregularly shaped physical supports and linking said nucleic acids thereto.

1 / 7




Figure 1/1

2 / 7




Figure 1/2

3 / 7




Figure 1/3

4 / 7




Figure 2/1

5 / 7




Figure 2 / 2

6/7




Figure 3a

7/7




Figure 3b

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 95/00109

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO-A-94 01582 (MEDICAL RES COUNCIL ;SIBSON DAVID ROSS (GB)) 20 January 1994	14-16, 19-22
A	see page 56; claims; figures	1-8
X	EP,A,0 392 546 (RO INST ZA MOLEKULARNU GENETIK) 17 October 1990	30
A	see page 7, line 45 - line 50; claims 9,16,17	1-29
A	EP-A-0 309 969 (DU PONT DE NEMOURS AND CO.) 5 April 1989	1-8
	see page 5, line 9 - page 8, line 57; examples 10,11	
A	WO,A,89 03432 (US ENERGY) 20 April 1989	1-8
	see the whole document	
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

9 June 1995

Date of mailing of the international search report

- 3. 07. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Molina Galan, E

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB 95/00109

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,91 06678 (STANFORD RES INST INT ;TSIEN ROGER Y (US)) 16 May 1991 see the whole document ---	9-12
A	GENOMICS, vol. 4, 1989 SAN DIEGO, US, pages 114-128, DRMANAC ET AL 'Sequencing of megabase plus DNA by hybridisation: theory of the method' cited in the application ---	
A	WO,A,93 24654 (BOEHRINGER MANNHEIM GMBH ;SAGNER GREGOR (DE); KESSLER CHRISTOPH (D) 9 December 1993 -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB95/00109

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims: 1-29: Method of sequencing nucleic acids
2. Claims: 30: Method of ordering nucleic acids

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Pat. Appl. No.

PCT/GB 95/00109

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9401582	20-01-94	AU-B- 4575893 CA-A- 2139944 EP-A- 0650528	31-01-94 20-01-94 03-05-95
EP-A-0392546	17-10-90	JP-A- 2299598	11-12-90
EP-A-309969	05-04-89	US-A- 5102785 JP-A- 1137983	07-04-92 30-05-89
WO-A-8903432	20-04-89	US-A- 4962037 EP-A- 0381693 JP-T- 3502041	09-10-90 16-08-90 16-05-91
WO-A-9106678	16-05-91	EP-A- 0450060	09-10-91
WO-A-9324654	09-12-93	DE-A- 4218152 EP-A- 0597076 JP-T- 6504208	09-12-93 18-05-94 19-05-94